摘要
目的研究冠心病(coronary heart disease,CHD)合并高脂血症患者采用瑞舒伐他汀治疗的临床疗效。方法选取CHD合并高脂血症患者共200例,随机分为试验组和对照组,每组100例。对照组予以血脂康治疗,试验组予以瑞舒伐他汀治疗。对比2组患者治疗8周后血脂[总胆固醇(TC)、低密度脂蛋白(HDL-C)]、超敏C-反应蛋白(hs-CRP)、白介素-6(IL-6)、一氧化氮(NO)、内皮素-1(ET-1)和血液流变学指标(全血高切黏度、血浆黏度、纤维蛋白原、血小板聚集率)。结果试验组治疗后的TG、TC和LDL显著低于对照组,HDL显著高于对照组,差异有统计学意义(P<0.05)。试验组患者治疗后的hs-CRP、IL-6、ET-1显著低于对照组,NO显著高于对照组,差异有统计学意义(P<0.05)。试验组患者治疗后的全血高切黏度、血浆黏度、纤维蛋白原和血小板聚集率显著低于对照组(P<0.05)。结论和血脂康比较,瑞舒伐他汀治疗CHD合并高脂血症可有效降低血脂和炎症水平,改善血粘度和内皮功能。
Objective To analyze the clinical efficacy of rosuvastatin in patients with coronary heart disease （ CHD） complicated by hyperlipidemia .Methods Two hundred patients with CHD complicated by hyperlipidemia who were treated in our hospital from June 2012 to June 2014 were randomly divided into trial group and control group ,with 100 patients in each group.The patients in control group were treated by Xuezhikang , however, the patients in trial group were treated by rosuvastatin .After 8-week treatment , the levels of total cholesterol （ TC） , low density lipoprotein cholesterol （ LDL-C） , high density lipoprotein （ HDL ） , highsensitivity C reactive protein （ hs-CRP ） , interleukin-6 （ IL-6 ） , nitric oxide （ NO ） , endothelin-1 （ET-1） and haemorheology indexes including high shear whole blood viscosity , plasma viscosity, fibrinogen, platelet aggregation rate were detected and compared between two groups .Results After treatment the levels of TG , TC, and LDL-C in trial group were significantly lower than those in control group （ P 〈0.05）.The levels of hs-CRP, IL-6, ET-1 in trial group were significantly lower than those in control group , however , the levels of NO were significantly higher than those in control group （ P 〈0.05）.The high shear whole blood viscosity ,plasma viscosity,fibrinogen and platelet aggregation rate in trial group were significantly lower than those in control group （ P 〈0.05）.Conclusion As compared with Xuezhikang , rosuvastatin can effectively reduce the levels of blood lipids and inflammatory factors and can improve blood viscosity and endothelial function of patients with CHD complicated by hyperlipidemia .
出处
《河北医药》
CAS
2016年第16期2419-2421,共3页
Hebei Medical Journal
关键词
冠心病
高脂血症
瑞舒伐他汀
coronary heart disease
hyperlipidemia
rosuvastatin
